カテゴリー： Allied Market Research, 世界, 医療/バイオ

エクソソーム診断・治療のグローバル市場（2021-2030）：診断、治療

◆英語タイトル：Exosome Diagnostic and Therapeutic Market By Application (Diagnostic, Therapeutic), By Product (Instrument, Reagent, Software), By End User (Cancer Institute, Hospital, Diagnostic Center, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030

Allied Market Researchが発行した調査報告書（ALD23OCT094）◆商品コード：ALD23OCT094
◆発行会社（リサーチ会社）：Allied Market Research
◆発行日：2023年8月
◆ページ数：110
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

世界のエクソソーム診断・治療市場は、2020年に224.3百万ドルと評価され、2021年から2030年までの年平均成長率は29.4%を記録し、2030年には2,928.8百万ドルに達すると予測されています。エクソソームは、唾液、尿、血液、母乳などさまざまな体液中に存在する小さな細胞外小胞です。これらの小胞は、細胞間情報伝達プロセスにおいて重要な役割を果たしており、タンパク質、脂質、メッセンジャーリボ核酸（mRNA）、マイクロリボ核酸（RNA）からなる特異的な組成を有しています。現在、エクソソームは薬物送達や様々な疾患の診断・検査のためのバイオマーカーとして利用される大きな可能性を秘めています。さらに、エクソソームは、さまざまな種類のがんの診断と管理に使用される侵襲的生検の代替経路を提供します。世界のエクソソーム診断・治療市場は、癌の有病率の増加、政府や非政府団体によるイニシアチブの拡大、健康意識の高まり、エクソソーム分離の技術的進歩、分析手順の急増、エクソソームの革新的で高度な応用の増加によって牽引されています。しかし、エクソソーム診断・治療製品の承認に関する政府の厳しい規制や、エクソソームの応用に関する認識不足が市場の成長を制限しています。
さらに、中国やインドなどの発展途上国は、この市場に大きな成長機会をもたらすと期待されています。エクソソーム診断・治療市場は、用途、製品、エンドユーザー、地域によって区分されます。用途別では、診断用途と治療用途に二分されます。
製品別では、装置、試薬、ソフトウェアに分類されます。エンドユーザー別では、がん研究所、病院、診断センター、その他（医科大学、非営利団体）に分類されます。地域別では、北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカで分析されます。北米は2020年に市場を席巻し、研究開発投資の増加、エクソソーム分離手順の技術進歩、癌罹患率の上昇などの要因により、予測期間中もその優位性を維持すると予想されます。また、アジア太平洋地域は、主要企業の発展途上国への注力の増加、臨床研究・試験のアウトソーシングの増加、国民の健康に対する意識と関心の高まり、がんおよびその他の慢性疾患の発生率の急増により、最大の成長可能性を持つ地域として浮上すると予想されます。

本レポートでは、エクソソーム診断・治療市場で事業を展開する主要企業には、Aethlon Medical, Inc.（アメリカ）、Exosome Diagnostics Inc.（アメリカ）、NanoSomix Inc.（アメリカ）、Thermo Fisher Scientific Inc. (イギリス）、System Biosciences Inc.（アメリカ）、NX Pharmagen（アメリカ）、Sistemic Inc.（イギリス）、Capricor Therapeutics（アメリカ）、Exiqon A/S（デンマーク）などが含まれます。

ステークホルダーにとっての主なメリット
2020年から2030年までの市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、市場の有力な機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

本レポートをご購入いただくと、以下の特典があります：
四半期ごとの更新可能です*（コーポレート・ライセンスの場合のみ、表示価格でのご提供となります）
ご購入前またはご購入後に、ご希望の企業プロフィールを5つ無料で追加できます。
無料のアップデートとして、購入前または購入後に、5社の会社概要を追加可能です。
アナリストによる16時間のサポート可能です。* (購入後、レポートのレビューで追加のデータ要件が見つかった場合、質問や販売後の問い合わせを解決するためにアナリストによる16時間のサポートを受けることができます)
15% の無料カスタマイズ可能です。* （レポートの範囲またはセグメントが要件と一致しない場合、20% は 3 営業日の無料作業に相当し、1 回適用されます。）
5ユーザー・エンタープライズユーザーライセンスの無料データパック可能です。(Excel版レポート）
レポートが6～12ヶ月以上前の場合、無料更新可能です。
24時間優先対応可能です。
産業の最新情報とホワイトペーパーを無料で提供します。

本レポートで可能なカスタマイズ（追加費用とスケジュールが必要です。）
製品ベンチマーク／製品仕様と用途
製品／セグメント別の市場シェア分析
主要プレイヤーの新製品開発／製品マトリックス
顧客の関心に応じた追加的な企業プロフィール
国または地域の追加分析-市場規模と予測
平均販売価格分析／価格帯分析
企業プロファイルの拡張リスト
過去の市場データ
SWOT分析

主要市場セグメント

用途別
診断
治療

製品別
機器
試薬
ソフトウェア

エンドユーザー別
がん研究所
病院
診断センター
その他

地域別：
北米
アメリカ
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
中国
日本
インド
韓国
その他のアジア太平洋地域
中南米・中東・アフリカ
中南米
中東
アフリカ

主な市場プレイヤー
Waabi
Aurora Innovation Inc.
PlusAI, Inc.
Kodiak Robotics, Inc.
Embark Trucks, Inc.
Einride
RRAI
TuSimple
Jiluo Technology (Shanghai) Co., Ltd.
Torc Robotics

第1章. 序章
第2章. エグゼクティブサマリー
第3章. 市場概要
第4章. エクソソーム診断・治療の市場分析：用途別
第5章. エクソソーム診断・治療の市場分析：製品別
第6章. エクソソーム診断・治療の市場分析：エンドユーザー別
第7章. エクソソーム診断・治療の市場分析：地域別
第8章. 競争状況
第9章. 企業情報

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of chronic diseases
3.4.1.2. Increase in prevalence of cancer
3.4.1.3. Rise in number of geriatric populations

3.4.2. Restraints
3.4.2.1. Lack of product approvals for exosome diagnostic and therapeutic technique

3.4.3. Opportunities
3.4.3.1. Rise in adoption of key strategies

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Diagnostic
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Therapeutic
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT
5.1. Overview
5.1.1. Market size and forecast
5.2. Instrument
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Reagent
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Software
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Cancer Institute
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Hospital
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Diagnostic Center
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Application
7.2.3. Market size and forecast, by Product
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by Product
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by Product
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by Product
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Application
7.3.3. Market size and forecast, by Product
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by Product
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by Product
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. U.K.
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by Product
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by Product
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by Product
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by Product
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Application
7.4.3. Market size and forecast, by Product
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by Product
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by Product
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. Rest of Asia-Pacific
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by Product
7.4.5.3.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Application
7.5.3. Market size and forecast, by Product
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by Product
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by Product
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by Product
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by Product
7.5.5.4.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2020
CHAPTER 9: COMPANY PROFILES
9.1. Aethlon Medical, Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Key strategic moves and developments
9.2. Exosome Diagnostic, Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Key strategic moves and developments
9.3. NanoSomix, Inc
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.4. Thermo Fisher Scientific, Inc.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Malvern Instruments Ltd
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.6. System Biosciences, Inc
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. NX Pharmagen, Inc.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Sistemic Ltd
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Capricor Therapeutics, Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Exiqon A/S
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio

LIST OF TABLES
TABLE 01. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 02. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC, BY REGION, 2020-2030 ($MILLION)
TABLE 03. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR THERAPEUTIC, BY REGION, 2020-2030 ($MILLION)
TABLE 04. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 05. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR INSTRUMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 06. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR REAGENT, BY REGION, 2020-2030 ($MILLION)
TABLE 07. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR SOFTWARE, BY REGION, 2020-2030 ($MILLION)
TABLE 08. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 09. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR CANCER INSTITUTE, BY REGION, 2020-2030 ($MILLION)
TABLE 10. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR HOSPITAL, BY REGION, 2020-2030 ($MILLION)
TABLE 11. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC CENTER, BY REGION, 2020-2030 ($MILLION)
TABLE 12. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 13. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 15. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 16. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 17. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 18. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 19. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 20. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 21. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 22. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 23. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 24. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 25. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 26. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 27. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 28. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 29. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 30. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 31. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 32. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 33. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 34. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 35. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 36. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 37. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 38. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 39. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 40. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 41. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 42. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 44. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 45. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 46. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 47. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 48. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 49. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 50. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 51. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 52. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 53. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 54. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 55. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 56. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 57. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 58. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 60. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 61. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 62. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 63. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 64. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 65. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 66. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 67. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 68. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 69. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 70. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 71. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 72. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 73. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 74. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 75. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 76. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 77. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 78. AETHLON MEDICAL, INC.: KEY EXECUTIVES
TABLE 79. AETHLON MEDICAL, INC.: COMPANY SNAPSHOT
TABLE 80. AETHLON MEDICAL, INC.: PRODUCT SEGMENTS
TABLE 81. AETHLON MEDICAL, INC.: PRODUCT PORTFOLIO
TABLE 82. AETHLON MEDICAL, INC.: KEY STRATERGIES
TABLE 83. EXOSOME DIAGNOSTIC, INC.: KEY EXECUTIVES
TABLE 84. EXOSOME DIAGNOSTIC, INC.: COMPANY SNAPSHOT
TABLE 85. EXOSOME DIAGNOSTIC, INC.: PRODUCT SEGMENTS
TABLE 86. EXOSOME DIAGNOSTIC, INC.: PRODUCT PORTFOLIO
TABLE 87. EXOSOME DIAGNOSTIC, INC.: KEY STRATERGIES
TABLE 88. NANOSOMIX, INC: KEY EXECUTIVES
TABLE 89. NANOSOMIX, INC: COMPANY SNAPSHOT
TABLE 90. NANOSOMIX, INC: PRODUCT SEGMENTS
TABLE 91. NANOSOMIX, INC: PRODUCT PORTFOLIO
TABLE 92. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
TABLE 93. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 94. THERMO FISHER SCIENTIFIC, INC.: PRODUCT SEGMENTS
TABLE 95. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 96. MALVERN INSTRUMENTS LTD: KEY EXECUTIVES
TABLE 97. MALVERN INSTRUMENTS LTD: COMPANY SNAPSHOT
TABLE 98. MALVERN INSTRUMENTS LTD: PRODUCT SEGMENTS
TABLE 99. MALVERN INSTRUMENTS LTD: PRODUCT PORTFOLIO
TABLE 100. SYSTEM BIOSCIENCES, INC: KEY EXECUTIVES
TABLE 101. SYSTEM BIOSCIENCES, INC: COMPANY SNAPSHOT
TABLE 102. SYSTEM BIOSCIENCES, INC: PRODUCT SEGMENTS
TABLE 103. SYSTEM BIOSCIENCES, INC: SERVICE SEGMENTS
TABLE 104. SYSTEM BIOSCIENCES, INC: PRODUCT PORTFOLIO
TABLE 105. NX PHARMAGEN, INC.: KEY EXECUTIVES
TABLE 106. NX PHARMAGEN, INC.: COMPANY SNAPSHOT
TABLE 107. NX PHARMAGEN, INC.: PRODUCT SEGMENTS
TABLE 108. NX PHARMAGEN, INC.: PRODUCT PORTFOLIO
TABLE 109. SISTEMIC LTD: KEY EXECUTIVES
TABLE 110. SISTEMIC LTD: COMPANY SNAPSHOT
TABLE 111. SISTEMIC LTD: PRODUCT SEGMENTS
TABLE 112. SISTEMIC LTD: PRODUCT PORTFOLIO
TABLE 113. CAPRICOR THERAPEUTICS, INC.: KEY EXECUTIVES
TABLE 114. CAPRICOR THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 115. CAPRICOR THERAPEUTICS, INC.: SERVICE SEGMENTS
TABLE 116. CAPRICOR THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 117. EXIQON A/S: KEY EXECUTIVES
TABLE 118. EXIQON A/S: COMPANY SNAPSHOT
TABLE 119. EXIQON A/S: PRODUCT SEGMENTS
TABLE 120. EXIQON A/S: PRODUCT PORTFOLIO

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ エクソソーム診断・治療のグローバル市場（2021-2030）：診断、治療(Exosome Diagnostic and Therapeutic Market By Application (Diagnostic, Therapeutic), By Product (Instrument, Reagent, Software), By End User (Cancer Institute, Hospital, Diagnostic Center, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 造影剤注入装置のグローバル市場（2021-2030）：消耗品、注入装置、付属品
  • 自動ピルディスペンサー機械のグローバル市場（2021-2030）：集中型自動ディスペンサー機械、分散型自動ディスペンサー機械
  • 内視鏡用光ファイバーのグローバル市場（2021-2030）：内視鏡用ガラス製光ファイバー（GOF）、内視鏡用プラスチック製光ファイバー（POF）
  • 外科手術用ドリルのアメリカ市場（2021-2031）：器具、付属品

    • ◆H&Iグローバルリサーチのお客様（例）◆